Pharm

Molnupiravir

search

Molnupiravir, Lagevrio

  • See Also
  1. Covid19
  2. Paxlovid
  • Indications
  1. Under FDA review in early 2022, emergency approved for age 18 years and older
  2. Consider in high risk patients over age 18 years (see above, esp. if unvaccinated)
  • Contraindications
  1. Contraindicated in pregnancy (birth defect risk) and affects mutagenesis in sperm
    1. Women should use reliable Contraception for at least 4 days after use
    2. Men should use Condoms for 3 months after use
  • Mechanism
  1. Blocks Covid19 replication by inserting into the viral RNA
  • Dosing
  1. Take 4 capsules twice daily for 5 days (and start within 5 days of onset)
  • Efficacy
  1. NNT: 35 unvaccinated patients to prevent one hospitalization (similar to Monoclonal Antibody efficacy)
  2. Less effective than Paxlovid
  • Resources
  1. Molnupiravir (DailyMed)
    1. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1b0da643-ab23-4a0b-a9ec-a434522446d0
  • References
  1. (2022) Presc Lett 29(1): 1